280 related articles for article (PubMed ID: 17968685)
1. An overview of high-dose melphalan and stem cell transplantation in the treatment of AL amyloidosis.
Sanchorawala V; Seldin DC
Amyloid; 2007 Dec; 14(4):261-9. PubMed ID: 17968685
[TBL] [Abstract][Full Text] [Related]
2. Primary amyloidosis of the kidney.
Shafique S; Wetmore J; Almehmi A
W V Med J; 2010; 106(1):22-4. PubMed ID: 20088306
[TBL] [Abstract][Full Text] [Related]
3. Autologous stem-cell transplantation in progressing amyloidosis is associated with severe transplant-related toxicity.
Worel N; Schulenburg A; Mitterbauer M; Keil F; Rabitsch W; Kalhs P; Gisslinger H; Raderer M; Geissler K; Höcker P; Zielinski CC; Oberbauer R; Greinix HT
Wien Klin Wochenschr; 2006 Feb; 118(1-2):49-53. PubMed ID: 16489526
[TBL] [Abstract][Full Text] [Related]
4. High-dose melphalan versus melphalan plus dexamethasone for AL amyloidosis.
Lachmann HJ; Wechalekar AD; Gillmore JD
N Engl J Med; 2008 Jan; 358(1):91-2; author reply 92-3. PubMed ID: 18175386
[No Abstract] [Full Text] [Related]
5. Heart transplantation in systemic (AL) amyloidosis: a retrospective study of eight French patients.
Mignot A; Varnous S; Redonnet M; Jaccard A; Epailly E; Vermes E; Boissonnat P; Gandjbakhch I; Herpin D; Touchard G; Bridoux F
Arch Cardiovasc Dis; 2008 Sep; 101(9):523-32. PubMed ID: 19041836
[TBL] [Abstract][Full Text] [Related]
6. Renal response after high-dose melphalan and stem cell transplantation is a favorable marker in patients with primary systemic amyloidosis.
Leung N; Dispenzieri A; Fervenza FC; Lacy MQ; Villicana R; Cavalcante JL; Gertz MA
Am J Kidney Dis; 2005 Aug; 46(2):270-7. PubMed ID: 16112045
[TBL] [Abstract][Full Text] [Related]
7. High-dose melphalan versus melphalan plus dexamethasone for AL amyloidosis.
Lokhorst HM; Hazenberg BP; Croockewit A
N Engl J Med; 2008 Jan; 358(1):92; author reply 92-3. PubMed ID: 18172953
[No Abstract] [Full Text] [Related]
8. High-dose melphalan versus melphalan plus dexamethasone for AL amyloidosis.
Mehta J
N Engl J Med; 2008 Jan; 358(1):91; author reply 92-3. PubMed ID: 18175385
[No Abstract] [Full Text] [Related]
9. Successful reduced intensity allogeneic stem cell transplantation for systemic AL amyloidosis.
Imamura T; Ogata M; Kohno K; Tomo T; Ohtsuka E; Kikuchi H; Kadota J
Am J Hematol; 2006 Apr; 81(4):281-3. PubMed ID: 16550508
[TBL] [Abstract][Full Text] [Related]
10. High-dose melphalan versus melphalan plus dexamethasone for AL amyloidosis.
Comenzo RL; Steingart RM; Cohen AD
N Engl J Med; 2008 Jan; 358(1):92; author reply 92-3. PubMed ID: 18175384
[No Abstract] [Full Text] [Related]
11. Primary AL amyloid polyneuropathy successfully treated with high-dose melphalan followed by autologous stem cell transplantation.
Katoh N; Matsuda M; Yoshida T; Yazaki M; Morita H; Sakashita K; Ikeda S
Muscle Nerve; 2010 Jan; 41(1):138-43. PubMed ID: 19813189
[TBL] [Abstract][Full Text] [Related]
12. High-dose melphalan versus melphalan plus dexamethasone for AL amyloidosis.
Kumar S; Dispenzieri A; Gertz MA
N Engl J Med; 2008 Jan; 358(1):91; author reply 92-3. PubMed ID: 18172183
[No Abstract] [Full Text] [Related]
13. High-dose melphalan and autologous hematopoietic stem cell transplantation in primary amyloidosis: single-center results.
Charlinski G; Ziarkiewicz M; Boguradzki P; Wiater E; Torosian T; Dwilewicz-Trojaczek J; Wiktor-Jedrzejczak W
Transplant Proc; 2014 Oct; 46(8):2877-81. PubMed ID: 25380940
[TBL] [Abstract][Full Text] [Related]
14. Successful treatment of systemic amyloidosis with hepatic involvement and factor X deficiency by high dose melphalan chemotherapy and autologous stem cell reinfusion.
Breems DA; Sonneveld P; de Man RA; Leebeek FW
Eur J Haematol; 2004 Mar; 72(3):181-5. PubMed ID: 14962236
[TBL] [Abstract][Full Text] [Related]
15. Microbiologically documented infections in patients undergoing high-dose melphalan and autologous stem cell transplantation for the treatment of light chain amyloidosis.
Taimur S; Nader C; Lloyd-Travaglini C; Seldin DC; Sanchorawala V
Transpl Infect Dis; 2013 Apr; 15(2):187-94. PubMed ID: 23279695
[TBL] [Abstract][Full Text] [Related]
16. Modern treatment of amyloidosis: unresolved questions.
Dember LM
J Am Soc Nephrol; 2009 Mar; 20(3):469-72. PubMed ID: 19073820
[TBL] [Abstract][Full Text] [Related]
17. Recovery of acute renal failure and nephrotic syndrome following autologous stem cell transplantation for primary (AL) amyloidosis.
Snanoudj R; Mamzer-Bruneel MF; Hermine O; Grunfeld JP; Chauveau D
Nephrol Dial Transplant; 2003 Oct; 18(10):2175-7. PubMed ID: 13679499
[No Abstract] [Full Text] [Related]
18. [A case of primary amyloidosis].
Ardashev VN; Potekhin NP; Rukavitsyn OA; Borisov AG; Malysheva SA
Klin Med (Mosk); 2006; 84(6):56-9. PubMed ID: 16875072
[TBL] [Abstract][Full Text] [Related]
19. Myeloablative chemotherapy with stem cell rescue for the treatment of primary systemic amyloidosis: a status report.
Gertz MA; Lacy MQ; Dispenzieri A
Bone Marrow Transplant; 2000 Mar; 25(5):465-70. PubMed ID: 10713619
[TBL] [Abstract][Full Text] [Related]
20. Early intensification and autologous stem cell transplantation in patients with systemic AL amyloidosis: a single-centre experience.
Frossard V; Ketterer N; Rosselet A; Meier P; Cairoli A; Duchosal MA; Kovacsovics T
Ann Hematol; 2009 Jul; 88(7):681-5. PubMed ID: 19066891
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]